Chemotherapy options after progression to PARPi

ESGO eAcademy, Sandro Pignata, 340831

Mechanisms of resistance to PARPi in ovarian cancer

ESGO eAcademy, Gourley Charlie, 350675

Mechanisms of resistance to PARPi in ovarian cancer

ESGO eAcademy, Gourley Charlie, 340830

Pro and cons of palliative chemotherapy in relapsed ovarian cancer

ESGO eAcademy, Nicoletta Colombo, 340824

Scientific session 8: Palliative strategies to optimise care in gynaecological cancer - Q&A

ESGO eAcademy, Jalid Sehouli, 340822

SLN uterine cancer European perspective (anatomic and surgical aspects, implementation, learning)

ESGO eAcademy, Jan Persson, 340816

Lifetime award (Editor's choice)

ESGO eAcademy, Ignace Vergote, 348203

Lifetime award

ESGO eAcademy, Ignace Vergote, 343688

Presidential lecture

ESGO eAcademy, Faculty / Presenters, 343687

Presidential session and awards

ESGO eAcademy, Faculty / Presenters, 340811

Workshop: How to break bad news in gynae oncology - Recaps

ESGO eAcademy, Faculty / Presenters, 340804

State of the Art 5: Updated ESGO-ESTRO-ESP guidelines in endometrial cancer - Q&A

ESGO eAcademy, Nicole Concin, 340795

First-line maintenance with PARP inhibitors should be given to all patients with ovarian cancer-Con

ESGO eAcademy, Jonathan Ledermann, 340810

Communication in a team

ESGO eAcademy, Annette Hasenburg, 340803

ESGO ESTRO ESP Endometrial cancer guidelines: Advanced and relapsed disease

ESGO eAcademy, Domenica Lorusso, 340794

Early-stage disease and adjuvant treatment

ESGO eAcademy, Carien Creutzberg, 340793

Debate 2: First-line maintenance with PARP inhibitors should be given to all patients with ovarian cancer - Pro/Con

ESGO eAcademy, Faculty / Presenters, 340805

Communication cards

ESGO eAcademy, Icó Tóth, 340802

ESGO-ESTRO-ESP guidelines in endometrial cancer.Surgery in endometrial cancer

ESGO eAcademy, Nicole Concin, 340792

ESGO-ESTRO-ESP guidelines in endometrial cancer. Risk group stratification: Molecular markers

ESGO eAcademy, Remi Nout, 340791

Tumour board 1: Rare cervical cancers - Discussion

ESGO eAcademy, Faculty / Presenters, 340782

How to break bad news in gynae oncology

ESGO eAcademy, Jalid Sehouli, 340801

ESGO-ESTRO-ESP guidelines in endometrial cancer. Risk group stratification: Pathological parameters

ESGO eAcademy, Xavier Matias-Guiu, 340790

Fertility sparing surgery in FIGO "IB2" cervical cancer

ESGO eAcademy, Lukas Rob, 340781

Video abstract 3 - Orthotopic neo-bladder creation after cervical cancer

ESGO eAcademy, Ana Conde Adán, 340774

Video abstract 2: ID 827 - How to do retro-peritoneal en bloc posterior pelvic exenteration in advanced ovarian cancer: Hudson-Dellepiane procedure in 10 steps

ESGO eAcademy, Nicolo Bizzarri, 340773

Video abstract 1: ID 630 - Vesico-vaginal fistula repair in a case of cancer cervix: A robotic assisted technique

ESGO eAcademy, Shylasree TS, 340772

Small cell cancer cervical cancer 2B

ESGO eAcademy, David Tan, 340780

State of the art 4: Role of radiomics and novel imaging in gynaecological cancer - Q&A

ESGO eAcademy, Anna Fagotti, 340764

Video session 1: Pelvic and vulva reconstruction - Q&A

ESGO eAcademy, Faculty / Presenters, 340771

Tumour Board 14: Cervical cancer in pregnancy

ESGO eAcademy, Alexandros Rodolakis, 340779

What we can achieve with US in gynaecologic oncology. Ready for radiomics?

ESGO eAcademy, Daniela Fischerova, 340763

Vulva reconstruction techniques

ESGO eAcademy, Sven Mahner, 340770

Radiomics in gynaecological cancer: MRI, CT scan and PET

ESGO eAcademy, Andrea Rockall, 340762

Bowel reconstruction techniques

ESGO eAcademy, Christina Fotopoulou, 340768

Debate 1: Is it time to implement molecular classification in the management of endometrial cancer? - Q&A

ESGO eAcademy, Faculty / Presenters, 340756

Why should a medical oncologist care about the molecular subtype of their endometrial cancer patients?

ESGO eAcademy, Alexandra Leary, 340755

Why should staging be adapted based on the molecular endometrial cancer subtype?

ESGO eAcademy, Frederic Amant, 340754

Eliminating cervical cancer - EUP vision

ESGO eAcademy, Chrysoula Zacharopoulou, 344365

Why should pathologists embrace the molecular endometrial cancer classification?

ESGO eAcademy, Tjalling Bosse, 340753

Eliminating cervical cancer - WHO vision

ESGO eAcademy, Princess Nothemba Simelela, 344366

What does women´s health mean for women's cancer?

ESGO eAcademy, Jalid Sehouli, 344367

WHO Keynote session: Eliminating cervical cancer in the EU and beyond: A global engagement - Q&A

ESGO eAcademy, Marc Arbyn, 344369

State of the art 3: Treating gynaecological cancer in the elderly and frail population - Q&A

ESGO eAcademy, Faculty / Presenters, 340740

The medical oncologist´s perspective

ESGO eAcademy, Jonathan Ledermann, 340747

Scientific session 6: Role of extrabdominal surgery in ovarian cancer - Q&A

ESGO eAcademy, Faculty / Presenters, 340733

The gyneco-oncologist´s perspective

ESGO eAcademy, Anna Fagotti, 340746

Multisystem toxicity in the elderly and frail: What can we learn from the NASA countermeasures program?

ESGO eAcademy, Jessica Scott, 340739

2nd ESO Ovarian Cancer Observatory:The clinical genetist´s perspective

ESGO eAcademy, JUDITH BALMAÑA, 340745

Management of thoracic disease and abdominal wall metastases in ovarian cancer

ESGO eAcademy, Philipp Harter, 340732

Frail patients and surgery

ESGO eAcademy, Kristina Lindemann, 340738

2nd ESO Ovarian Cancer Observatory:The clinical scientist´s perspective

ESGO eAcademy, Gourley Charlie, 340744

2nd ESO Ovarian Cancer Observatory:The pathologist´s perspective

ESGO eAcademy, Xavier Matias-Guiu, 340743

Management of brain and extra-abdominal lymph node metastases in ovarian cancer

ESGO eAcademy, Giovanni Scambia, 340731

Chemotherapy in vulnerable older patients with advanced ovarian cancer - the challenge of complexity

ESGO eAcademy, Gilles Freyer, 340737

New Frontiers in Treating Metastatic Cervical Cancer From Revolutionary Molecules to Clinical Therapies

ESGO eAcademy, Faculty / Presenters, 340726

Q&A - State of the art 2: Precision medicine in gynaecological oncology

ESGO eAcademy, Cristiana Sessa, 340717

Scientific session 5: ESGO quality indicators in endometrial cancer surgery - Q&A

ESGO eAcademy, Jan Persson, 340721

Identifying truly „actionable“ alterations: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

ESGO eAcademy, Cristiana Sessa, 340718

Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort

ESGO eAcademy, Stefan Kommoss, 343681

Efficacy of niraparib by timing of Surgery and residual disease: Post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

ESGO eAcademy, Roisin O’Cearbhaill, 343679

Impact of co-medication on survival in patients with ovarian cancer - Analysis of 4 prospective trials of the AGO-OVAR and ENGOT/GCIG collaborators

ESGO eAcademy, Dominik Denschlag, 343677

Survival in advanced stage epithelial ovarian cancer patients with cardiophrenic lymphadenopathy who underwent cytoreductive surgery: Meta-analysis

ESGO eAcademy, Malika Kengsakul, 343675

QIs on lymph node staging

ESGO eAcademy, Jan Persson, 343672

QIs related to patient management and to surgical performance in general

ESGO eAcademy, Cagatay Taskiran, 343671

How to develop, how to use and future implications of Qis

ESGO eAcademy, Nicole Concin, 343670

Precision oncology in endometrial cancer: Might be the best example!

ESGO eAcademy, Alexandra Leary, 343669

PARP inhibition in ovarian cancer: Are we delivering precision medicine?

ESGO eAcademy, Shannon Westin, 343668

Does platinum rechallenge have a role in the management of endometrial cancer?

ESGO eAcademy, Faculty / Presenters, 340713

Scientific session 3: Prehabilitation and enhanced recovery in gynaecological oncology - Q&A

ESGO eAcademy, Faculty / Presenters, 340704

State of the art 1: Cervical cancer screening in the era of HPV testing - Q&A

ESGO eAcademy, Faculty / Presenters, 340696

KORE Innovation trial

ESGO eAcademy, Jalid Sehouli, 340703

Scientific session 4: Immune checkpoint inhibitors in ovarian cancer - lessons learnt and the road ahead - Q&A

ESGO eAcademy, Faculty / Presenters, 340710

Balance oncological and reproductive outcomes when treating cervical disease - 2020 ESGO-EFC Terminology for cone dimensions

ESGO eAcademy, Maria Kyrgiou, 340695

Implementation of an ERAS prehabilitation program

ESGO eAcademy, ESTER MIRALPEIX, 340702

Challenges and perspective for immunotherapy combinations in ovarian cancer

ESGO eAcademy, Christian Marth, 340709

HPV screening and triage: ESGO-endorsed kits to be used

ESGO eAcademy, Marc Arbyn, 340694

Reduction in patient morbidity in an ERAS program

ESGO eAcademy, Stephanie Schneider, 340701

Cervical cancer elimination: A 100-year-old dream is becoming a reality

ESGO eAcademy, Murat Gultekin, 340693

Overall patient outcomes in ERAS gynaecologic oncology

ESGO eAcademy, Pedro Ramirez, 340700

Immunotherapy in ovarian cancer: from biological findings to clinical trials

ESGO eAcademy, Sandro Pignata, 340708

Scientific session 2: Challenges in surgical, radio-therapeutic and medical treatment of obese patients - Q&A

ESGO eAcademy, Faculty / Presenters, 340689

Scientific session 1: Ultrasound session - Q&A

ESGO eAcademy, Faculty / Presenters, 340682

Effect of body mass index on the election and effectiveness of medical treatment of gynaecologic cancers

ESGO eAcademy, Shannon Westin, 340688

Preoperative diagnosis of uterine fibroids and sarcomas

ESGO eAcademy, Dirk Timmerman, 340681

Radiotherapy as a safe and effective curative treatment in the patients with morbid obesity

ESGO eAcademy, Elzbieta van der Steen-Banasik, 340687

Cervical cancer staging (live scan)

ESGO eAcademy, Daniela Fischerova, 340680

KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer

ESGO eAcademy, Nicoletta Colombo, 343660

Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer

ESGO eAcademy, Ignace Vergote, 343662

Results of the Avoiding Late Diagnosis of Ovarian Cancer (ALDO) Project; a pilot national surveillance program for BRCA mutation-carriers

ESGO eAcademy, Adam Rosenthal, 343664

Results of NSGO-OV-UMB1/ENGOT-OV30 study: A phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)

ESGO eAcademy, Faculty / Presenters, 343666

Should we tailor the standard surgical treatment in obese patients?

ESGO eAcademy, Nadeem R. Abu-Rustum, 340686